Two investigators in Gilead’s Phase III remdesivir trials were unsurprised at recent protocol changes. However, they said enrollment in the moderate-disease study was slow due to difficulty capturing those patients, with one also citing publicity-driven interest in two unproven malaria drugs.

LEAVE A REPLY

Please enter your comment!
Please enter your name here